SSG
BIB icon

Summit Securities Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Summit Securities Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$13K – 400
2014
Q4 		$13K Buy
+200
New +$11.7K ﹤0.01% 434

Other funds holding BIB

VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return

Summit Securities Group's BIB Position: Q1 2015 in Review

Summit Securities Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2015, closing a stake of 200 shares — an estimated $13K sold.

Summit Securities Group first reported a position in BIB in Q4 2014 and held it in 1 quarter. The position peaked at $13K in Q4 2014. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2015.

  • Summit Securities Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2015 after selling out during the quarter.
  • Summit Securities Group sold 200 ProShares Ultra NASDAQ Biotechnology shares in Q1 2015, an estimated $13K.
  • Summit Securities Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and held it in 1 quarter.
  • Summit Securities Group's ProShares Ultra NASDAQ Biotechnology position peaked at $13K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2015.

Based on Summit Securities Group's 13F filing for Q1 2015, filed 22 Apr 2015.